Trade Krystal Biotech, Inc. - KRYS CFD

Krystal Biotech, Inc. Company profile

About Krystal Biotech Inc

Krystal Biotech, Inc. is a clinical stage biotechnology company focused on redosable gene delivery for the treatment of serious rare diseases. Using its platform that is based on engineered herpes simplex virus type 1 (HSV-1), the Company create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The Company’s gene therapy product candidates and undertaking preclinical studies and clinical trials of B-VEC, KB105, KB301, KB104, KB407 and KB408. The Company's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, and dehydration.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Krystal Biotech Inc revenues was not reported. Net loss increased from $32.2M to $69.6M. Higher net loss reflects General and Administrative - Balancing increase from $12.8M to $30.2M (expense), Stock-based Compensation in SGA increase from $2.3M to $10.2M (expense), Research and Development - Balancing increase of 44% to $24.5M (expense).